#1 Clinical Trials Search in Europe

Edoxaban

Edoxaban is an oral anticoagulant medication being studied in several clinical trials for its effectiveness and safety in treating various cardiovascular conditions. These trials are investigating edoxaban’s potential in preventing stroke in atrial fibrillation patients, resolving blood clots, and managing thrombosis in cancer patients. The studies aim to provide valuable insights into edoxaban’s real-world use and its impact on patient outcomes across different clinical scenarios.

Table of Contents

What is Edoxaban?

Edoxaban is a medication that belongs to a class of drugs called non-vitamin K antagonist oral anticoagulants (NOACs). It is also known by the brand name Lixiana[1]. Edoxaban is a type of blood thinner that works by selectively inhibiting a blood clotting factor called Factor Xa[2].

Uses of Edoxaban

Edoxaban is primarily used to treat and prevent various conditions related to blood clots. Its main uses include:

  • Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (an irregular heart rhythm) who have one or more risk factors such as:
    • Congestive heart failure
    • High blood pressure
    • Age 75 years or older
    • Diabetes
    • Previous stroke or transient ischemic attack (mini-stroke)[3]
  • Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults[4]
  • Prevention of catheter-related thrombosis in cancer patients[5]
  • Resolution of left atrial appendage thrombi (blood clots in a specific part of the heart) in patients with atrial fibrillation[6]

How Edoxaban Works

Edoxaban works by inhibiting Factor Xa, an important component in the blood clotting process. By blocking this factor, edoxaban helps prevent the formation of blood clots and reduces the risk of stroke and other clot-related complications[2]. This mechanism of action makes it effective in various conditions where blood clot prevention is crucial.

Dosage and Administration

Edoxaban is typically taken orally once daily. The dosage may vary depending on the specific condition being treated and individual patient factors. Common dosages include:

  • 60 mg once daily for most patients
  • 30 mg once daily for patients with one or more of the following:
    • Moderate to severe kidney impairment
    • Low body weight (60 kg or less)
    • Use of certain medications that interact with edoxaban[7]

It’s important to take edoxaban exactly as prescribed by your healthcare provider. In some cases, such as for patients with feeding tubes, edoxaban can be crushed and administered through the tube[8].

Effectiveness

Clinical trials and real-world studies have shown that edoxaban is effective in preventing stroke and systemic embolism in patients with atrial fibrillation. It has demonstrated similar or better efficacy compared to traditional blood thinners like warfarin, with a potentially better safety profile[3].

Edoxaban has also shown promise in treating and preventing deep vein thrombosis and pulmonary embolism, as well as in resolving blood clots in the heart’s left atrial appendage[6].

Side Effects and Safety

Like all medications, edoxaban can cause side effects. The most common and important side effect to be aware of is bleeding. This can include:

  • Major bleeding (including intracranial bleeding)
  • Clinically relevant non-major bleeding
  • Minor bleeding[7]

Other potential side effects may include anemia, nausea, and skin rash. It’s crucial to discuss any unusual symptoms or concerns with your healthcare provider.

Edoxaban should be used with caution in patients with certain conditions, such as severe kidney or liver disease. Your doctor will consider your individual risk factors when prescribing this medication.

Ongoing Research

Several clinical trials are currently underway to further investigate the use of edoxaban in various patient populations and conditions. These studies aim to:

  • Evaluate the use of edoxaban in cancer patients to prevent catheter-related thrombosis[5]
  • Assess the effectiveness of edoxaban in resolving blood clots in the left atrial appendage[6]
  • Study the pharmacokinetics (how the body processes the drug) of edoxaban in specific patient populations[9]
  • Investigate the use of edoxaban in patients who have undergone transcatheter aortic valve implantation (TAVI)[2]

These ongoing studies will help to further refine the use of edoxaban and potentially expand its applications in various clinical settings.

Aspect Details
Main Conditions Studied Non-valvular atrial fibrillation, venous thromboembolism in cancer patients, left atrial appendage thrombosis
Dosage Typically 60 mg once daily, with 30 mg dose for certain patient groups
Primary Outcomes Thrombus resolution, stroke prevention, bleeding events, quality of life
Study Durations Ranging from 4 weeks to 12 months or more
Special Populations Cancer patients, fragile patients with PEG tubes, patients with high creatinine clearance
Safety Assessments Bleeding events, liver adverse events, all-cause mortality
Unique Aspects Real-world evidence collection, pharmacokinetic/pharmacodynamic studies, comparison with other anticoagulants

FAQ

  • What is edoxaban and how does it work? Edoxaban is an oral anticoagulant medication that works by inhibiting factor Xa, a key component in the blood clotting process. It helps prevent the formation of blood clots and reduces the risk of stroke and other thromboembolic events in patients with certain cardiovascular conditions.
  • In which conditions is edoxaban being studied? Edoxaban is being studied in various conditions, including non-valvular atrial fibrillation, venous thromboembolism in cancer patients, left atrial appendage thrombosis, and catheter-related thrombosis in cancer patients. These trials aim to evaluate its efficacy and safety in different clinical scenarios.
  • How is edoxaban administered in these clinical trials? In most trials, edoxaban is administered orally once daily. The typical dose is 60 mg, but some patients may receive a reduced dose of 30 mg based on factors such as body weight, kidney function, or use of certain medications that interact with edoxaban.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include the resolution of blood clots, prevention of stroke and systemic embolism, incidence of bleeding events, quality of life, and overall safety profile. Some trials also assess pharmacokinetics and pharmacodynamics of edoxaban in specific patient populations.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, ranging from a few weeks to up to 12 months or more. Some studies include additional follow-up periods to assess long-term outcomes and safety. The length of the trial depends on the specific research objectives and the condition being studied.

Ongoing Clinical Trials on Edoxaban

  • Study on the Effectiveness of Tenecteplase in Patients with Acute Ischemic Stroke Taking Rivaroxaban, Apixaban, or Edoxaban

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Norway Sweden

  • Study on the Safety of Edoxaban for Patients with Porto-Sinusoidal Vascular Disorder

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Finland France Germany Greece +5

  • Study on Short-term Interruption vs. Continuous Anticoagulation with Apixaban in Patients Undergoing Colorectal Polypectomy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on the Safety of Continuing Apixaban, Clopidogrel, and Rivaroxaban During Polyp Removal in Patients on Antiplatelet or Anticoagulant Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Edoxaban and Drug Combination for Patients with Atrial Fibrillation Needing Anticoagulation After Cardiac Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Edoxaban for Patients with Atrial Fibrillation and Coronary Syndrome Undergoing PCI

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Italy The Netherlands

  • Study on Stopping Anticoagulants in Atrial Fibrillation Patients After Surgery: Warfarin, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Sweden

Glossary

  • Atrial Fibrillation: An irregular and often rapid heart rhythm that can lead to blood clots in the heart. It increases the risk of stroke, heart failure, and other heart-related complications.
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs (deep vein thrombosis) or lungs (pulmonary embolism).
  • Left Atrial Appendage (LAA): A small, ear-shaped sac in the muscle wall of the left atrium. It's a common site for blood clot formation in patients with atrial fibrillation.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Factor Xa: An enzyme involved in the blood clotting process. Edoxaban works by inhibiting this factor to prevent clot formation.
  • Creatinine Clearance: A test that measures how well your kidneys are working by estimating how much blood passes through the glomeruli each minute.
  • Transesophageal Echocardiography (TEE): A test that uses sound waves to create detailed pictures of your heart and the arteries that lead to and from it.
  • CHADS2-VAS score: A clinical prediction rule for estimating the risk of stroke in patients with atrial fibrillation.
  • Percutaneous Endoscopic Gastrostomy (PEG): A procedure to place a flexible feeding tube through the abdominal wall and into the stomach.

References

  1. https://clinicaltrials.gov/study/NCT03489395
  2. https://clinicaltrials.gov/study/NCT04171726
  3. https://clinicaltrials.gov/study/NCT03247569
  4. https://clinicaltrials.gov/study/NCT03247582
  5. https://clinicaltrials.gov/study/NCT06149533
  6. https://clinicaltrials.gov/study/NCT03840291
  7. https://clinicaltrials.gov/study/NCT02964949
  8. https://clinicaltrials.gov/study/NCT06285942
  9. https://clinicaltrials.gov/study/NCT05320627